{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:55:40Z","timestamp":1791107740289,"version":"4.1.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":684,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1002\/hep.26437","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T10:25:11Z","timestamp":1365071111000},"page":"1897-1906","source":"Crossref","is-referenced-by-count":21,"title":["Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial"],"prefix":"10.1097","volume":"58","author":[{"given":"Zobair","family":"Younossi","sequence":"first","affiliation":[{"name":"Center for Liver Diseases and Department of Medicine; Inova Fairfax Hospital; Falls Church VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Negro","sequence":"additional","affiliation":[{"name":"Divisions of Clinical Pathology, and of Gastroenterology and Hepatology; University Hospital; Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Serfaty","sequence":"additional","affiliation":[{"name":"Liver Unit; H\u00f4pital St Antoine; UPMC Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes; INSERM Unit\u00e9 1016, and Assistance Publique-H\u00f4pitaux de Paris, Cochin Hospital; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moises","family":"Diago","sequence":"additional","affiliation":[{"name":"Hospital General de Valencia; Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[{"name":"Johann Wolfgang Goethe University Medical Center; Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Andreone","sequence":"additional","affiliation":[{"name":"Universit\u00e0 di Bologna; Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Lawitz","sequence":"additional","affiliation":[{"name":"Alamo Medical Research; San Antonio TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology; Alfred Hospital; Melbourne VIC Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Focaccia","sequence":"additional","affiliation":[{"name":"Emilio Ribas Infectious Diseases Institute; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[{"name":"Queen Marys University of London; Institute of Cell and Molecular Science; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Horban","sequence":"additional","affiliation":[{"name":"Warsaw Medical University and Hospital of Infectious Diseases; Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lonjon-Domanec","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceuticals; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Coate","sequence":"additional","affiliation":[{"name":"Janssen Research & Development; LLC Titusville NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"DeMasi","sequence":"additional","affiliation":[{"name":"Janssen Research & Development; LLC Titusville NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston","family":"Picchio","sequence":"additional","affiliation":[{"name":"Janssen Research & Development; LLC Titusville NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Witek","sequence":"additional","affiliation":[{"name":"Janssen Research & Development; LLC Titusville NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2013,10,17]]},"reference":[{"key":"10.1002\/hep.26437-BIB0001|hep26437-cit-0001","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jhep.2008.08.006","article-title":"Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis","volume":"49","author":"White","year":"2008","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26437-BIB0002|hep26437-cit-0002","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/hep.22703","article-title":"Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C","volume":"49","author":"Arase","year":"2009","journal-title":"Hepatology"},{"key":"10.1002\/hep.26437-BIB0003|hep26437-cit-0003","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/hep.25867","article-title":"Sustained virological response prevents development of insulin resistance in chronic hepatitis C patients","volume":"56","author":"Aghemo","year":"2012","journal-title":"Hepatology"},{"key":"10.1002\/hep.26437-BIB0004|hep26437-cit-0004","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/jhep.2003.09012","article-title":"Impaired IRS-1\/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes","volume":"38","author":"Aytug","year":"2003","journal-title":"Hepatology"},{"key":"10.1002\/hep.26437-BIB0005|hep26437-cit-0005","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0002-9440(10)63408-6","article-title":"Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3","volume":"165","author":"Kawaguchi","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1002\/hep.26437-BIB0006|hep26437-cit-0006","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/hep.21634","article-title":"The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms","volume":"45","author":"Pazienza","year":"2007","journal-title":"Hepatology"},{"key":"10.1002\/hep.26437-BIB0007|hep26437-cit-0007","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/hep.23031","article-title":"Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C","volume":"50","author":"Vanni","year":"2009","journal-title":"Hepatology"},{"key":"10.1002\/hep.26437-BIB0008|hep26437-cit-0008","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1053\/j.gastro.2009.11.050","article-title":"Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance","volume":"138","author":"Milner","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.26437-BIB0009|hep26437-cit-0009","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2036.2011.04716.x","article-title":"Meta-analysis: insulin resistance and sustained virological response in hepatitis C","volume":"34","author":"Eslam","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/hep.26437-BIB0010|hep26437-cit-0010","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jhep.2011.03.010","article-title":"Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis","volume":"55","author":"Deltenre","year":"2011","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26437-BIB0011|hep26437-cit-0011","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","article-title":"Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients","volume":"128","author":"Romero-Gomez","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.26437-BIB0012|hep26437-cit-0012","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jhep.2007.07.026","article-title":"Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3","volume":"48","author":"Poustchi","year":"2008","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26437-BIB0013|hep26437-cit-0013","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/ajg.2010.110","article-title":"Insulin resistance predicts rapid virologic response to peginterferon\/ribavirin combination therapy in hepatitis C genotype 4 patients","volume":"105","author":"Khattab","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/hep.26437-BIB0014|hep26437-cit-0014","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.21455","article-title":"Race, insulin resistance and hepatic steatosis in chronic hepatitis C","volume":"45","author":"Conjeevaram","year":"2007","journal-title":"Hepatology"},{"key":"10.1002\/hep.26437-BIB0015|hep26437-cit-0015","first-page":"401A","article-title":"Telaprevir in combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment-na\u00efve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study","volume":"52","author":"Sherman","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/hep.26437-BIB0016|hep26437-cit-0016","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.26437-BIB0017|hep26437-cit-0017","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.26437-BIB0018|hep26437-cit-0018","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1136\/gutjnl-2011-300749","article-title":"Insulin resistance and response to telaprevir plus peginterferon \u03b1 and ribavirin in treatment-naive patients infected with HCV genotype 1","volume":"61","author":"Serfaty","year":"2012","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1002\/hep.26437-BIB0019|hep26437-cit-0019","first-page":"375A","article-title":"Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon\/ribavirin treatment failure: post-hoc analysis of the phase III REALIZE study","volume":"54","author":"Berg","year":"2011","journal-title":"Hepatology"},{"key":"10.1002\/hep.26437-BIB0020|hep26437-cit-0020","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","article-title":"Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]","volume":"125","author":"Hui","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.26437-BIB0021|hep26437-cit-0021","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jhep.2004.09.022","article-title":"Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients","volume":"42","author":"Muzzi","year":"2005","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26437-BIB0022|hep26437-cit-0022","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1572-0241.2008.01813.x","article-title":"Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection","volume":"103","author":"Petta","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/hep.26437-BIB0023|hep26437-cit-0023","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.gastro.2007.11.010","article-title":"Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis","volume":"134","author":"Moucari","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.26437-BIB0024|hep26437-cit-0024","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/hep.22251","article-title":"Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus","volume":"47","author":"Veldt","year":"2008","journal-title":"Hepatology"},{"key":"10.1002\/hep.26437-BIB0025|hep26437-cit-0025","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1158\/1055-9965.EPI-08-1131","article-title":"The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses","volume":"18","author":"Wang","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1002\/hep.26437-BIB0026|hep26437-cit-0026","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1365-2036.2011.04635.x","article-title":"IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C","volume":"33","author":"Fattovich","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/hep.26437-BIB0027|hep26437-cit-0027","doi-asserted-by":"crossref","unstructured":"Ueki K Kondo T Tseng YH Kahn CR Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse Proc Natl Acad Sci U S A 2004 101 10422 10427","DOI":"10.1073\/pnas.0402511101"},{"key":"10.1002\/hep.26437-BIB0028|hep26437-cit-0028","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jhep.2005.04.004","article-title":"Signalling links in the liver: knitting SOCS with fat and inflammation","volume":"43","author":"Farrell","year":"2005","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26437-BIB0029|hep26437-cit-0029","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1096\/fj.02-0664fje","article-title":"IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3","volume":"17","author":"Bode","year":"2003","journal-title":"FASEB J"},{"key":"10.1002\/hep.26437-BIB0030|hep26437-cit-0030","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1128\/MCB.00224-09","article-title":"Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18\/UBP43","volume":"29","author":"Sarasin-Filipowicz","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1002\/hep.26437-BIB0031|hep26437-cit-0031","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/liv.12031","article-title":"Intrahepatic mRNA levels of the suppressors of cytokine signalling 1 and 3 mRNA are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C","volume":"33","author":"Pascarella","year":"2013","journal-title":"Liver Int"},{"key":"10.1002\/hep.26437-BIB0032|hep26437-cit-0032","first-page":"475","article-title":"Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance","volume":"17","author":"Bortoletto","year":"2010","journal-title":"J Viral Hepat"},{"key":"10.1002\/hep.26437-BIB0033|hep26437-cit-0033","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/hep.24394","article-title":"Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: a vicious circle of clinical significance?","volume":"54","author":"Franceschini","year":"2011","journal-title":"Hepatology"},{"key":"10.1002\/hep.26437-BIB0034|hep26437-cit-0034","first-page":"585","article-title":"Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis?","volume":"55","author":"Tarantino","year":"2006","journal-title":"Gut"},{"key":"10.1002\/hep.26437-BIB0035|hep26437-cit-0035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jhep.2008.03.033","article-title":"Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin","volume":"49","author":"Overbeck","year":"2008","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26437-BIB0036|hep26437-cit-0036","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1478-3231.2009.02171.x","article-title":"Pioglitazone improves virological response to peginterferon alpha-2b\/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance","volume":"30","author":"Khattab","year":"2010","journal-title":"Liver Int"},{"key":"10.1002\/hep.26437-BIB0037|hep26437-cit-0037","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jhep.2009.02.014","article-title":"Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?","volume":"50","author":"Serfaty","year":"2009","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26437-BIB0038|hep26437-cit-0038","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/hep.25661","article-title":"Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin","volume":"56","author":"Harrison","year":"2012","journal-title":"Hepatology"},{"key":"10.1002\/hep.26437-BIB0039|hep26437-cit-0039","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/gut.51.1.89","article-title":"Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C","volume":"51","author":"Hickman","year":"2002","journal-title":"Gut"},{"key":"10.1002\/hep.26437-BIB0040|hep26437-cit-0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ajg.2011.384","article-title":"Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study","volume":"107","author":"Lai","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/hep.26437-BIB0041|hep26437-cit-0041","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1210\/jc.2010-2415","article-title":"Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients","volume":"96","author":"Nkontchou","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/hep.26437-BIB0042|hep26437-cit-0042","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.26437-BIB0043|hep26437-cit-0043","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.26437-BIB0044|hep26437-cit-0044","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hep.21774","article-title":"Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C","volume":"46","author":"Forestier","year":"2007","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/hep.26437-BIB0045|hep26437-cit-0045","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(11)60015-9","article-title":"Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon\/ribavirin treatment failure: subanalysis of the REALIZE Phase III study","volume":"54","author":"Pol","year":"2011","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26437-BIB0046|hep26437-cit-0046","doi-asserted-by":"crossref","first-page":"S542","DOI":"10.1016\/S0168-8278(11)61371-8","article-title":"Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial","volume":"54","author":"Jacobson","year":"2011","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26437-BIB0047|hep26437-cit-0047","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep.23690","article-title":"Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin","volume":"52","author":"Akuta","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/hep.26437-BIB0048|hep26437-cit-0048","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/hep.25949","article-title":"Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis","volume":"56","author":"Akuta","year":"2012","journal-title":"Hepatology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26437","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/hep.26437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T12:41:48Z","timestamp":1673440908000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hep.26437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,17]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26437","archive":["Portico"],"relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10,17]]}}}